Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM180VX)

Drug Name
SC-49483 Drug Info
Synonyms
Glycovir; 131262-82-3; UNII-QXJ91425UL; DRG-0193; NSC 670880; Perbutylated-N-butyl-1-deoxynojiromycin; SC 49483; QXJ91425UL; N-Butyl DNJ Prodrug; Butanoic acid, 1-butyl-2-((1-oxobutoxy)methyl)-3,4,5-piperidinetriyl ester, (2R-(2alpha,3beta,4alpha,5beta))-; SC-48334 Prodrug; NSC670880; SC49483; AC1L1TYK; 1,5-(Butylimino)-1-5-dideoxy-D-glucitol tetrabutanoate; AC1Q60AI; SCHEMBL5967912; DTXSID10156986; NSC-670880; DB13106; LS-46130; 1-Butyl-2R,4.alpha.,5.beta.-piperidinetriyl butanoate
Indication
Disease Entry ICD 11 Status REF
Acquired immune deficiency syndrome 1C62.3 Phase 2 [1]
Cross-matching ID
PubChem CID
60807
CAS Number
CAS 131262-82-3
TTD Drug ID
DM180VX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Intestinal maltase-glucoamylase (MGAM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Voglibose DMUBP9O Diabetic complication 5A2Y Approved [3]
Acarbose DMRM3AW Diabetic complication 5A2Y Approved [4]
Miglitol DMXBQAM Diabetic complication 5A2Y Approved [5]
Rh-alphaglucosidase DMNF0G8 Pompe disease 5C51.3 Approved [6]
Deoxynojirimycin DM2ATZB Pompe disease 5C51.3 Phase 3 [7]
Alpha-glucosidase DM2RTGP Muscle disease FB3Z Phase 3 [8]
PAZ-320 DMU0812 Type-2 diabetes 5A11 Phase 2 [9]
Maltose DMH0ROP N. A. N. A. Phase 1/2 [10]
SALACINOL DMVKQT8 N. A. N. A. Phase 1/2 [11]
Celgosivir DMD1V7I Dengue fever 1D2Z Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Intestinal maltase-glucoamylase (MGAM) TTXWASR MGA_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT00000791) A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV. U.S. National Institutes of Health.
2 Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
3 Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
6 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
7 Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
9 Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
10 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
11 Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
12 Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.Curr Opin Investig Drugs.2009 Aug;10(8):860-70.